the costeffectiveness of different screening approaches.
PrEP has strong potential to decrease new HIV infections among MSM if imple mented effectively. With the recognition that medicationadherent MSM who use PrEP are unlikely to acquire HIV but are poten tially at increased risk of HCV infection and other nonHIV STIs, information about risk factors, screening and diagnosis of HCV must be integrated into educational interven tions for MSM who use PrEP and improved information for their clinicians. In this way, comprehensive PrEP care could provide an opportunity for MSM and clinicians to avert incident HIV infections, improve clinical out comes for MSM who newly acquire HCV and prevent forward transmission of HCV though earlier diagnosis and appropriate treatment.
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N e w s & V i e w s
The one thing that we have learned about prostate cancer risk stratification over the past 30 years is that the use of serum PSA testing and transrectal ultrasonography (TRUS)guided biopsy in tandem -as a diagnostic interven tion -fails to identify men who are at risk of a premature prostatecancerrelated death 1 . Two main explanations for this failure exist. The first relates to the high degree of imprecision of the combined tests, and the second pertains to the high rate of missed diagnoses and over diagnosis that occurs when the two tests are combined. Consequently, the combined outputs of PSA testing and TRUSguided biopsy are only weakly associated with the known principal risk factors of tumour grade, stage and volume 2 . The introduction of multiparametric MRI (mpMRI) into the prostate cancer diagnostic pathway has provided an opportunity to iden tify men who have a true risk of premature death, given that positive findings on mpMRI are positively associated with tumour grade, stage and volume 3, 4 . However, we still need to decide where to draw the line in terms of dis ease severity -above which we would reco mmend treatment and below which we would not. Ultimately, this threshold will need to be calibrated by the probability of a premature prostatecancerrelated death if left untreated. The late 2018 update from the SPCG4 study, reporting 29year followup data, gives us some idea of where this threshold might lie, given the maturity of the data 2 . The SPCG4 study ran domized men with prostate cancer to radical prostatectomy or conservative management. These men presented clinically as recruitment occurred in the prePSA era, which is impor tant given that the clinical manifestation of dis ease, just like an abnormal finding on mpMRI, tends to be positively associated with high tumour grade, stage and volume. Moreover, in the radical prostatectomy arm, the investi gators reported grade and stage accurately and used this precise risk stratification to predict
To see or not to see -what renders prostate cancer visible?
Mark Emberton
Multiparametric MRI (mpMRI) has revolutionized prostate cancer diagnosis and risk stratification, but the question remains regarding what it is that we see (or don't see) on mpMRI. A new study by Houlahan and colleagues now offers insight into the molecular characteristics of a tumour that influence mpMRI visibility. (Likert 1-2) 3 . Thus, few, if any, truly clinically relevant pro state cancers should be missed using the new imageguided diagnostic pathway.
These data are reassuring for future patients in terms of appropriate and effective risk stratification, but the question remains as to what it is being seen (or not seen) when an mpMRI of the prostate is scrutinized and used as the principal riskstratification tool. A recent study by Houlahan and colleagues 5 helps considerably in this regard. Using a pro cess of selection and rejection of cases, the authors managed to curate a cohort of 40 men who had tumours described as Gleason 3 + 4 (in their prostatectomy specimen) that met or exceeded a maximum of 1.5 cm in diameter. In half of the men, the tumour was declared 'non visible' on mpMRI as a consequence of having a Prostate Imaging Reporting and Data System version 2 (PIRADS v2) score of 1-2. Tumours from the other half of the cohort were declared 'very visible' as a consequence of having a PIRADS v2 score of 5. Despite the contin gencies of the case selection process, the men with mpMRIvisible PIRADS v2 5 lesions had a higher tumour volume and pathologi cal stage, a greater proportion of Gleason pat tern 4 and a higher prevalence of cribriform architecture than their mpMRIinvisible PIRADS v2 1-2 counterparts. The investi gators hypothesized that mpMRI invisibility reflected key molecular characteristics of the tumours and, accordingly, performed genome and transcriptome profiling in all 40 tumours, which revealed that mpMRIvisible tumours were enriched for aggressive molecular and microenvironmental features.
The question remains as to whether the intriguing observation by Houlahan and The observation that cancers that are vis ible on mpMRI are worse (in terms of pro pensity to invade and metastasize) than those that are not visible should be selfevident, as it seems to hold true for all other solid can cers. In no solid organ, other than prostate, do we seek to procure and interrogate tissue in the presence of a nonsuspicious mpMRI. If the SPCG4 results 2 hold true -as these data will not be challenged for a considera ble time, during which other cohorts will mature -a non suspicious mpMRI (PIRADS v2 score 1-2) might be unlikely to be associated with underlying pathological features that are associated with a prostatecancerrelated death.
Perhaps the next step is to improve our understanding of the determinants and fate of the rich spectrum of endotypes that prostate mpMRI provides us with, such that we might gain insight into the cancer that we are seeing and, in so doing, improve our ability to classify it (possibly without recourse to biopsy) and, in time, predict its fate and the patient's outcome 10 .
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e-mail: m.emberton@ucl.ac.uk coworkers 5 that mpMRI conspicuity (as deter mined by a PIRADS v2 score of 5 versus 1-2) was associated with molecular changes that we would normally associate with an increased propensity for progression was attributable to the mpMRIderived phenotype itself, or whether mpMRIvisible cancers were merely larger, of proportionally higher grade and more invasive than mpMRIinvisible tumours.
First, what makes a prostate tumour visible on mpMRI must be considered. Ultimately, visibility is determined by the degree to which tumourrelated attributes (the signal), which are specifically interrogated by the imaging sequence, differ from the background prostate (the noise), such that the naked eye (and in the future the software) might be able to detect a boundary between the two. Many reasons -over and above issues relating to tumour volume, a proxy for the number of tumour cells present -exist to suggest that tumours that are visible on mpMRI might be more aggressive than those that are not visible. The observation that a given tumour can exhibit a strong sig nal on the dynamic contrastenhanced (DCE) T1gadolinium sequence implies the establish ment of an abnormal, tumourmediated blood supply that could promote further tumour cell proliferation 6 . Furthermore, the presence of a low apparent diffusion coefficient (ADC) tends to be associated with increased cell den sity, a status that is conferred by a tendency towards anaplasia and invasion, resulting in remodelling of the tissue microstructure 7 . Novel sequences are under development that interrogate other tissue attributes, such as the T2 quantification of luminal water, which, again, might provide insight into specific cancer subtypes 8 . Houlahan et al. 5 did not seek to classify which transcriptomic signal was associated with which mpMRIderived endotype (posi tive versus negative T2; positive versus negative DCE; high versus low ADC), an analysis that might have provided the greatest insight into the upstream drivers of tissue micro structure. Instead, they used the PIRADS v2 scoring system, a rulebased process that was designed to reduce interobserver vari ability in the reporting of prostate mpMRI. PIRADS scores are derived using a Boolean process that treats anatomically distinct parts of the prostate differently, places weight on some sequences over others and explicitly incorporates a volume threshold 9 . For these and other reasons, PIRADS v2 might not have been the best reference standard to use when seeking to understand the dominant signalling that is associated with the range of pheno typic features that we see when we look at prostate cancer, as expressed by the standard mpMRI sequences.
mpMRI-visible tumours were enriched for aggressive molecular and microenvironmental features
